The Journal of Immunology, Vol 159, Issue 1 167-174, Copyright © 1997 by American Association of Immunologists

ARTICLES

In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice

X Xu, L Blinder, J Shen, H Gong, A Finnegan, JW Williams and AS Chong
Department of General Surgery, Rush Medical College, Chicago, IL 60612, USA.

Two activities have been identified for the immunosuppressive metabolite of leflunomide, A77 1726: inhibition of dihydroorotate dehydrogenase (DHO-DHase), an enzyme involved in the biosynthesis of pyrimidine nucleotides (PyN); and inhibition of protein tyrosine kinases. The in vitro potency of A77 1726 as a DHO-DHase inhibitor is reported to be 10- to 500-fold greater than as a tyrosine kinase inhibitor. These observations suggested that the immunosuppressive efficacy of leflunomide in vivo is related to inhibition of DHO-DHase. However, observations that patients with disorders in the PyN synthetic pathway are not overtly immunodeficient militate against this hypothesis. We investigated the effects of leflunomide in vivo and report that amelioration of lymphoproliferative and autoimmune diseases in MRL/MpJ-lpr/lpr (lpr/lpr) mice by leflunomide is not accompanied by reduced PyN concentrations in lymph node cells. Our hypothesis that lymphocytes could salvage serum uridine to counter the effects of reduced PyN synthesis in vivo was supported by in vitro studies. Finally, we observed that amelioration of disease correlated with a reduction of tyrosine phosphorylated proteins in lymph node cells of lpr/lpr mice. These observations suggest that the primary mechanism by which leflunomide prevents autoimmune and lymphoproliferative diseases in lpr/lpr mice is not depletion of PyN, but correlates with reduced tyrosine phosphorylation concentrations in lymph node cells.

This article has been cited by other articles:

				H. Wang, T. Cui, F. Hou, Z. Ni, X. Chen, F. Lu, F. Xu, X. Yu, F. Zhang, X. Zhao, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study Lupus, July 1, 2008; 17(7): 638 - 644. [Abstract] [PDF]

				N. Leca, K. A. Muczynski, J. A. Jefferson, I. H. de Boer, J. Kowalewska, E. A. Kendrick, R. Pichler, and C. L. Davis Higher Levels of Leflunomide Are Associated with Hemolysis and Are not Superior to Lower Levels for BK Virus Clearance in Renal Transplant Patients Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 829 - 835. [Abstract] [Full Text] [PDF]

				S. K. Manna, A. Mukhopadhyay, and B. B. Aggarwal Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-{kappa}B, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis J. Immunol., November 15, 2000; 165(10): 5962 - 5969. [Abstract] [Full Text] [PDF]

				F C Breedveld and J-M Dayer Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann Rheum Dis, November 1, 2000; 59(11): 841 - 849. [Abstract] [Full Text]

				S. K. Manna and B. B. Aggarwal Immunosuppressive Leflunomide Metabolite (A77 1726) Blocks TNF-Dependent Nuclear Factor-{kappa}B Activation and Gene Expression J. Immunol., February 15, 1999; 162(4): 2095 - 2102. [Abstract] [Full Text] [PDF]

				K. Ruckemann, L. D. Fairbanks, E. A. Carrey, C. M. Hawrylowicz, D. F. Richards, B. Kirschbaum, and H. A. Simmonds Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans J. Biol. Chem., August 21, 1998; 273(34): 21682 - 21691. [Abstract] [Full Text] [PDF]

				X. Xu, H. Gong, L. Blinder, J. Shen, J. W. Williams, and A. S.-F. Chong Control of Lymphoproliferative and Autoimmune Disease in MRL-lpr/lpr Mice by Brequinar Sodium: Mechanisms of Action J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 869 - 875. [Abstract] [Full Text]